275 related articles for article (PubMed ID: 28240973)
1. Late Relapse of Classical Hodgkin Lymphoma: An Analysis of the German Hodgkin Study Group HD7 to HD12 Trials.
Bröckelmann PJ; Goergen H; Kohnhorst C; von Tresckow B; Moccia A; Markova J; Meissner J; Kerkhoff A; Ludwig WD; Fuchs M; Borchmann P; Engert A
J Clin Oncol; 2017 May; 35(13):1444-1450. PubMed ID: 28240973
[TBL] [Abstract][Full Text] [Related]
2. Young adults diagnosed with Hodgkin lymphoma are at risk of relapsing late: a comprehensive analysis of late relapse in Hodgkin lymphoma.
Pinczés L; Miltényi Z; Illés Á
J Cancer Res Clin Oncol; 2018 May; 144(5):935-943. PubMed ID: 29468437
[TBL] [Abstract][Full Text] [Related]
3. Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group.
Nogová L; Reineke T; Brillant C; Sieniawski M; Rüdiger T; Josting A; Bredenfeld H; Skripnitchenko R; Müller RP; Müller-Hermelink HK; Diehl V; Engert A;
J Clin Oncol; 2008 Jan; 26(3):434-9. PubMed ID: 18086799
[TBL] [Abstract][Full Text] [Related]
4. Relapsed hodgkin lymphoma in older patients: a comprehensive analysis from the German hodgkin study group.
Böll B; Goergen H; Arndt N; Meissner J; Krause SW; Schnell R; von Tresckow B; Eichenauer DA; Sasse S; Fuchs M; Behringer K; Klimm BC; Naumann R; Diehl V; Engert A; Borchmann P
J Clin Oncol; 2013 Dec; 31(35):4431-7. PubMed ID: 24190119
[TBL] [Abstract][Full Text] [Related]
5. Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials.
Behringer K; Mueller H; Goergen H; Thielen I; Eibl AD; Stumpf V; Wessels C; Wiehlpütz M; Rosenbrock J; Halbsguth T; Reiners KS; Schober T; Renno JH; von Wolff M; van der Ven K; Kuehr M; Fuchs M; Diehl V; Engert A; Borchmann P
J Clin Oncol; 2013 Jan; 31(2):231-9. PubMed ID: 23150709
[TBL] [Abstract][Full Text] [Related]
6. Late recurrence of lymphoid malignancies after initial treatment for Hodgkin lymphoma - A study from the Danish Lymphoma Registry.
Andersen MD; Hamilton-Dutoit S; Modvig L; Vase M; Christiansen I; Christensen JH; Dahl-Sørensen RB; Stoltenberg D; Kamper P; d'Amore F
Br J Haematol; 2022 Jul; 198(1):50-61. PubMed ID: 35396711
[TBL] [Abstract][Full Text] [Related]
7. Outcome of patients experiencing progression or relapse after primary treatment with two cycles of chemotherapy and radiotherapy for early-stage favorable Hodgkin's lymphoma.
Sieniawski M; Franklin J; Nogova L; Glossmann JP; Schober T; Nisters-Backes H; Diehl V; Josting A
J Clin Oncol; 2007 May; 25(15):2000-5. PubMed ID: 17420510
[TBL] [Abstract][Full Text] [Related]
8. The development of quality assurance programs for radiotherapy within the German Hodgkin Study Group (GHSG). Introduction, continuing work, and results of the radiotherapy reference panel.
Müller RP; Eich HT
Strahlenther Onkol; 2005 Sep; 181(9):557-66. PubMed ID: 16170482
[TBL] [Abstract][Full Text] [Related]
9. Analyses of patterns-of-failure and prognostic factors according to radiation fields in early-stage Hodgkin lymphoma.
Krebs L; Amorin S; Brice P; Guillerm S; Menard J; Hennequin C; Quéro L
Strahlenther Onkol; 2017 Feb; 193(2):116-124. PubMed ID: 27316376
[TBL] [Abstract][Full Text] [Related]
10. Characteristics and outcomes of patients with nodular lymphocyte-predominant Hodgkin lymphoma versus those with classical Hodgkin lymphoma: a population-based analysis.
Gerber NK; Atoria CL; Elkin EB; Yahalom J
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):76-83. PubMed ID: 25863756
[TBL] [Abstract][Full Text] [Related]
11. Lymphocyte-rich classical Hodgkin's lymphoma: clinical presentation and treatment outcome in 100 patients treated within German Hodgkin's Study Group trials.
Shimabukuro-Vornhagen A; Haverkamp H; Engert A; Balleisen L; Majunke P; Heil G; Eich HT; Stein H; Diehl V; Josting A
J Clin Oncol; 2005 Aug; 23(24):5739-45. PubMed ID: 16009944
[TBL] [Abstract][Full Text] [Related]
12. Subsequent malignancies among long-term survivors of Hodgkin lymphoma and non-Hodgkin lymphoma: a pooled analysis of German cancer registry data (1990-2012).
Baras N; Dahm S; Haberland J; Janz M; Emrich K; Kraywinkel K; Salama A
Br J Haematol; 2017 Apr; 177(2):226-242. PubMed ID: 28106907
[TBL] [Abstract][Full Text] [Related]
13. Favorable prognosis after late relapse of Hodgkin's disease.
Garcia-Carbonero R; Paz-Ares L; Arcediano A; Lahuerta J; Bartolome A; Cortes-Funes H
Cancer; 1998 Aug; 83(3):560-5. PubMed ID: 9690550
[TBL] [Abstract][Full Text] [Related]
14. Lymphocyte-depleted classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin study group.
Klimm B; Franklin J; Stein H; Eichenauer DA; Haverkamp H; Diehl V; Fuchs M; Borchmann P; Engert A
J Clin Oncol; 2011 Oct; 29(29):3914-20. PubMed ID: 21911729
[TBL] [Abstract][Full Text] [Related]
15. Impact of Bleomycin and Vincristine Dose Reductions in Patients With Advanced Hodgkin Lymphoma Treated With BEACOPP: An Analysis of the German Hodgkin Study Group HD12 and HD15 Trials.
Haverkamp H; Böll B; Eichenauer DA; Sasse S; Fuchs M; Borchmann P; Diehl V; Engert A; von Tresckow B
J Clin Oncol; 2015 Aug; 33(22):2430-6. PubMed ID: 26101245
[TBL] [Abstract][Full Text] [Related]
16. Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study.
Hentrich M; Berger M; Wyen C; Siehl J; Rockstroh JK; Müller M; Fätkenheuer G; Seidel E; Nickelsen M; Wolf T; Rieke A; Schürmann D; Schmidmaier R; Planker M; Alt J; Mosthaf F; Engert A; Arasteh K; Hoffmann C
J Clin Oncol; 2012 Nov; 30(33):4117-23. PubMed ID: 23045592
[TBL] [Abstract][Full Text] [Related]
17. [Treatment results of stage IA Hodgkin lymphoma: a report of 97 cases].
Tan WY; Hu DS; Zeng FY; Song QB; Hu S; Wei L; Zhou LQ
Ai Zheng; 2007 Dec; 26(12):1360-4. PubMed ID: 18076802
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the Risk of Relapse in Classical Hodgkin Lymphoma at Event-Free Survival Time Points and Survival Comparison With the General Population in British Columbia.
Hapgood G; Zheng Y; Sehn LH; Villa D; Klasa R; Gerrie AS; Shenkier T; Scott DW; Gascoyne RD; Slack GW; Parsons C; Morris J; Pickles T; Connors JM; Savage KJ
J Clin Oncol; 2016 Jul; 34(21):2493-500. PubMed ID: 27269949
[TBL] [Abstract][Full Text] [Related]
19. Increased healthcare use up to 10 years among relapse-free Hodgkin lymphoma survivors in the era of intensified chemotherapy and limited radiotherapy.
Glimelius I; Eloranta S; Ekberg S; Chang ET; Neovius M; Smedby KE
Am J Hematol; 2017 Mar; 92(3):251-258. PubMed ID: 28006849
[TBL] [Abstract][Full Text] [Related]
20. Sick leave and disability pension in Hodgkin lymphoma survivors by stage, treatment, and follow-up time--a population-based comparative study.
Glimelius I; Ekberg S; Linderoth J; Jerkeman M; Chang ET; Neovius M; Smedby KE
J Cancer Surviv; 2015 Dec; 9(4):599-609. PubMed ID: 25689964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
